3月24日 - ** 生物技术公司Hoth Therapeutics HOTH.O股价上涨约7%，至0.07美元左右
** 该公司称其实验性外用药物HT-001有助于缓解表皮生长因子受体（EGFR）癌症疗法引起的皮肤问题，这种疗法通常会导致皮疹和刺激症状
** 表皮生长因子受体（EGFR）疗法是一种常见的癌症治疗方法，它能阻断有助于肿瘤生长的信号，但它会损害健康皮肤，影响患者的生活质量 - HOTH
** 公司称，重复使用 HT-001 可使局部药物暴露增加约 77%，而血液吸收率非常低，低于口服药物的 0.5%
** 称未报告严重副作用，也没有患者因安全问题停止治疗
** 2025 年股价上涨约 32%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.